Market Snapshot August 4, 2009, 4:25PM EST

Stocks Finish Higher

(page 2 of 2)

Story Tools

UBS AG (UBS) posted CHF 0.39 second quarter loss, vs. CHF 0.16 loss a year ago, on 66% drop in interest income. The Swiss bank says results include an own credit charge of CHF 1.213 billion, restructuring charges of CHF 582 million and a goodwill impairment charge of CHF 492 million related to the announced sale of UBS Pactual. It says in spite of positive economic signs, the overall economic environment in most of the regions in which it operates remains recessionary; says sustainable recovery is not yet visible.

Cognizant Technology Solutions (CTSH) reported $0.50, vs. $0.39, second quarter non-GAAP EPS on 13% revenue rise. It sees third quarter revenue of at least $800 million, $0.44 non-GAAP EPS. It raised 2009 revenue growth guidance from at least 10% to at least 11.5%; now expects 2009 revenue of at least $3.14B, at least $1.80 non-GAAP EPS.

Marvel Entertainment (MVL) posted $0.37, vs. $0.59, second quarter EPS on 26% sales decline. The Street was looking for $0.31. It raised the low end of its sales and EPS guidance for 2009; it now sees $1.25-$1.35 EPS on $465-$485 million revenue vs. prior guidance of $1.10-$1.35 EPS on $450-$485 million revenue.

Tenet Healthcare (THC) reported a second quarter loss of $0.03 per share, which was $0.02 short of the First Call consensus that expected a loss of a penny per share. Revenue declined 5.5% year-over-year to $2.23 billion vs. the $2.22 billion consensus. The company sees fiscal year 2009 loss of $0.08 to $0.01 per share (analyts expect a loss of $0.01) and revenue of $8.9 billion to $9.1 billion (vs. the $8.98 billion consensus).

Pulte Homes (PHM) posted $0.74 second quarter loss, vs. $0.63 loss, on 58% revenue decline. Lower revenues for the quarter primarily reflect a year-over-year decline in homes closed in the quarter, combined with a decrease in average selling price.

Archer-Daniels-Midland (ADM) posted $0.10, vs. $0.58, fourth quarter EPS on 24% drop in sales and other operating income.

CVS Caremark (CVS) posted $0.65, vs. $0.60, second quarter adjusted EPS from continued operations on 18% revenue rise. Given its strong performance year to date and optimism for the rest of the year, it raises its EPS guidance and narrows range. The drug store operator now expects to deliver 2009 adjusted EPS from continuing operations of $2.59-$2.64, up from previous guidance of $2.55-$2.63.

McCormack is senior producer for BusinessWeek.com's Investing channel.